Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rinn Song

Clinical Scientist

Dr. Rinn Song joined OVG and the Department of Paediatrics in September 2017 as a Clinician-Scientist and Honorary Consultant in Paediatric Infectious Diseases. Dr. Song completed his medical studies at the Ludwig-Maximilians-University in Munich, Germany, with an MD and a Doctorate Degree in Medicine (MD Res) with a focus on Health Services Research. He completed his clinical training in Paediatrics at New York University in New York, USA, followed by training in Applied Epidemiology and Public Health as an Epidemic Intelligence Service Officer in the TB Division of the US Centers for Disease Control and Prevention. Up until joining the University of Oxford, he has been an affiliated Scientist with the TB Division of the CDC. He completed his training in Paediatric Infectious Diseases at Boston Children’s Hospital/Harvard Medical School and then joined the faculty of the Department of Paediatrics of Harvard Medical School in 2012. He has been a Consultant in Paediatric Infectious Diseases at Boston Children’s Hospital since 2012 and is board certified in Paediatrics and Paediatric Infectious Diseases by the American Board of Pediatrics. He holds an MPH from the Harvard School of Public Health and an MSc in Immunology of Infectious Diseases from the London School of Hygiene and Tropical Medicine. Dr. Song's primary research interest is paediatric TB, with a specific interest in paediatric TB diagnostics. He has been the PI of a 5 year NIH grant to investigate novel diagnostics as part of a study in Kenya, completed in collaboration with the CDC and KEMRI, and has also been recently working with FIND, Switzerland, on the development and evaluation of novel TB diagnostics.